The main direction proposed by the community of experts in the field of laser-driven ion acceleration is to improve particle beam features (maximum energy, charge, emittance, divergence, monochromaticity, shot-to-shot stability) in order to demonstrate reliable and compact approaches to be used for multidisciplinary applications, thus, in principle, reducing the overall cost of a laser-based facility compared to a conventional accelerator one and, at the same time, demonstrating innovative and more effective sample irradiation geometries. The mission of the laser-driven ion target area at ELI-Beamlines (Extreme Light Infrastructure) in Dolní Břežany, Czech Republic, called ELI Multidisciplinary Applications of laser-Ion Acceleration (ELIMAIA) , is to provide stable, fully characterized and tuneable beams of particles accelerated by Petawatt-class lasers and to offer them to the user community for multidisciplinary applications. The ELIMAIA beamline has been
A: Nowadays the innovative high power laser-based ion acceleration technique is one of the most interesting challenges in particle acceleration field, showing attractive characteristics for future multidisciplinary applications, including medical ones. Nevertheless, peculiarities of optically accelerated ion beams make mandatory the development of proper transport, selection and diagnostics devices in order to deliver stable and controlled ion beams for multidisciplinary applications. This is the main purpose of the ELIMAIA (ELI Multidisciplinary Applications of laser-Ion Acceleration) beamline that will be realized and installed within 2018 at the ELI-Beamlines research center in the Czech Republic, where laser driven high energy ions, up to 60 MeV/n, will be available for users. In particular, a crucial role will be played by the on-line diagnostics system, recently developed in collaboration with INFN-LNS (Italy), consisting of TOF detectors, placed along the beamline (at different detection distances) to provide online monitoring of key characteristics of delivered beams, such as energy, fluence and ion species. In this contribution an overview on the ELIMAIA available ion diagnostics will be briefly given along with the preliminary results obtained during a test performed with high energy laser-driven proton beams accelerated at the VULCAN PW-laser available at RAL facility (UK). K: Ion diagnostics; high energy laser-driven protons; time of flight.A X P : 1234.56789
Charged particle radiotherapy is currently used in an increasing number of centres worldwide. While protons are the most widely used ion species, carbon ions have shown many advantages for the treatment of radioresistant tumours, thanks to their higher Linear Energy Transfer (LET) and Relative Biological Effectiveness (RBE). The complexity and the high cost of conventional carbon therapy facilities has stimulated the investigation of alternative acceleration approaches such as the processes based on high-power laser interaction with solid targets. Recent developments in ion acceleration have allowed to investigate for the first time the biological effects of carbon ions at ultra-high dose-rate (109-1010 Gy/s) using the GEMINI laser system at Rutherford Appleton Laboratory (RAL). Carbon ions were accelerated from ultrathin (10-20 nm) carbon foils and energy selected by a magnet allowing to irradiate the cells with an average carbon energy of 10 MeV/u ± 8%. A dosimetry approach specifically designed for these low-energy ions was employed, which was based on the use of unlaminated EBT3 Radiochromic films. The details of the dosimetry arrangement as well as the Geant4 simulation performed to predict the energy and the dose distribution at the cell plane will be reported.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.